一、盟科药业募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上海盟科药业股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1204 号）同意，公司首次公开发 行的人民币普通股（A 股）13,000.00 万股（每股面值人民币 1.00 元），发行价格 为 8.16 元/股，本次发行募集资金总额为 106,080.00 万元，扣除各项发行费用（不 含增值税）人民币 10,107.21 万元后，实际募集资金净额为 95,972.79 万元。普华 永道中天会计师事务所（特殊普通合伙）于 2022 年 8 月 2 日出具了普华永道中 天验字（2022）第 0564 号《验资报告》，验证募集资金已全部到位。 公司已将募集资金存放于为本次发行开立的募集资金专项账户，并与保荐机 构、存放募集资金的银行签署了《募集资金专户存储三方监管协议》。具体情况 详见公司于 2022 年 8 月 4 日披露于上海证券交易所网站（www.sse.com.cn）的 《首次公开发行股票科创板上市公告书》。 中国国际金融股份有限公司 关于上海盟科药业股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中国国际金 ...

证券代码：688373 证券简称：盟科药业 上海盟科药业股份有限公司 2023 年第一次临时股东大会 会议资料 上海盟科药业股份有限公司 2023 年第一次临时股东大会会议资料 二 O 二三年八月 | 2023 | 年第一次临时股东大会会议须知 2 | | --- | --- | | 2023 | 年第一次临时股东大会会议议程 4 | | | 议案一 6 | | | 关于补选公司第一届董事会独立董事的议案 6 | 上海盟科药业股份有限公司 2023 年第一次临时股东大会会议资料 上海盟科药业股份有限公司 2023 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的 顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》（以下简称"《证券法》"）《上市公司股东大会规则》以及《上海盟科 药业股份有限公司章程》（以下简称"《公司章程》"）、《上海盟科药业股份有限公 司股东大会议事规则》等相关规定，上海盟科药业股份有限公司（以下简称"公司"） 特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格， ...

重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年第一次临时股东大会 证券代码：688373 证券简称：盟科药业 公告编号：2023-037 上海盟科药业股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 合的方式 股东大会召开日期：2023年8月24日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 （四） 现场会议召开的日期、时间和地点 召开日期时间：2023 年 8 月 24 日 13 点 30 分 召开地点：中国（上海）自由贸易试验区爱迪生路 53 号 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 8 月 24 日 至 2023 年 8 月 24 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东 ...

上海盟科药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 7 月 6 日(星期四) 上午 09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 6 月 29 日(星期四) 至 7 月 5 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 688373@micurxchina.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 证券代码：688373 证券简称：盟科药业 公告编号：2023-027 上海盟科药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 25 日披露公司 2022 年度报告，于 2023 年 4 月 21 日披露公司 2023 年第一季度报告，为便于广大投资者更全面深 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥17,276,928.37, representing a year-on-year increase of 61.66%[6] - The net profit attributable to shareholders was -¥56,162,215.81, with a net profit excluding non-recurring gains and losses of -¥66,094,526.04[6] - Basic and diluted earnings per share were both -¥0.09[7] - Net profit for Q1 2023 was a loss of ¥56,162,215.81, compared to a loss of ¥51,037,472.73 in Q1 2022, indicating a deterioration in profitability[21] - The company reported a total comprehensive loss of ¥60,536,884.08 for Q1 2023, compared to a loss of ¥51,142,420.56 in Q1 2022[22] Cash Flow - The net cash flow from operating activities was -¥52,110,741.31[6] - Cash flow from operating activities showed a net outflow of ¥52,110,741.31 in Q1 2023, an improvement from a net outflow of ¥59,596,616.66 in Q1 2022[24] - Cash inflow from investment activities was ¥1,007,024,951.62 in Q1 2023, significantly higher than ¥367,679,389.19 in Q1 2022[24] - Cash outflow from investment activities totaled ¥936,466,469.01 in Q1 2023, compared to ¥310,864,930.21 in Q1 2022, reflecting increased investment activity[24] - Cash flow from financing activities resulted in a net outflow of ¥8,706,496.12 in Q1 2023, worsening from a net outflow of ¥2,407,742.71 in Q1 2022[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,434,639,407.35, down 4.19% from the end of the previous year[7] - As of March 31, 2023, the total current assets amounted to CNY 1,309,827,148.68, a decrease of 4.9% from CNY 1,370,505,453.28 at the end of 2022[16] - The total liabilities decreased to CNY 273,041,997.26 from CNY 283,095,971.09, indicating a reduction of 3.7%[17] - The company's total equity decreased to CNY 1,161,597,410.09 from CNY 1,214,274,089.45, a decline of 4.3%[17] - The company's short-term borrowings were reported at CNY 48,752,200.00, which is a new entry in the current liabilities section[17] Research and Development - Total R&D investment amounted to ¥43,468,902.65, an increase of 32.06% compared to the previous year[7] - R&D investment accounted for 251.60% of operating revenue, a decrease of 56.40 percentage points[7] - The company increased its academic promotion efforts, which contributed to the rapid growth in revenue[10] Inventory and Receivables - The company's inventory increased significantly to CNY 32,114,012.87 from CNY 21,888,500.05, marking an increase of 46.5%[16] - The total receivables decreased slightly to CNY 10,747,847.78 from CNY 11,102,134.08, a decline of 3.2%[14] Non-Recurring Items - The company reported a non-recurring gain of ¥9,932,310.23 during the period[9]

Financial Performance - The company reported a net profit attributable to the parent company of negative value, indicating it has not yet achieved profitability[4]. - The company's operating revenue for 2022 was CNY 48,206,746.85, representing a 529.33% increase compared to CNY 7,660,011.80 in 2021[24]. - The net profit attributable to shareholders of the listed company for 2022 was CNY -220,298,739.18, slightly improved from CNY -226,270,200.17 in 2021[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -267,648,089.96, compared to CNY -264,277,537.55 in the previous year[24]. - The cash flow generated from operating activities was CNY -240,008,344.56, worsening from CNY -180,982,532.97 in 2021[24]. - The basic earnings per share for 2022 was -0.38 CNY, slightly improved from -0.43 CNY in 2021[26]. - The weighted average return on equity improved to -29.52% in 2022 from -42.75% in 2021[26]. - The company reported a net loss attributable to shareholders of CNY 66,026,734.90 in Q3 2022, with a total of CNY 46,524,233.46 in Q4 2022[29]. - The company’s stock is listed on the Shanghai Stock Exchange under the code 688373[21]. Research and Development - The company has incurred significant research and development expenses, leading to an increase in cumulative unabsorbed losses[5]. - The company is in a research investment phase, focusing on innovative drug development for infectious diseases[4]. - The research and development efforts are directed towards addressing antibiotic resistance, particularly in the context of CRAB and CRE[16]. - The company has a robust pipeline with 1 marketed drug, 3 drugs in clinical stages, and 6 drugs in preclinical research[38]. - The company has established a drug conjugate platform to enhance drug targeting and improve pharmacokinetic properties[40]. - The company has established a comprehensive commercialization team and has successfully covered 320 hospitals, with hospital channel sales accounting for approximately 60%[39]. - The company is focusing on innovative drug development targeting unmet clinical needs in the field of infectious diseases[42]. - The company has established a technology platform for evaluating drug metabolism, enhancing its ability to develop prodrugs and soft drugs[88]. - The company is conducting clinical trials for multiple new drugs, including MRX-4 and MRX-8, with MRX-4 in the international multi-center clinical phase III[149]. Market and Product Development - The core product, Kangti Zuoan tablets, has been launched and is currently being sold, with multiple other products in clinical trials both domestically and internationally[4]. - Future outlook includes plans for market expansion and potential mergers and acquisitions to drive growth[16]. - The company plans to continue its dual-market development strategy in China and major Western markets to maximize the commercial value of its core products[41]. - The company is exploring distribution models in overseas markets to enhance commercial promotion and market entry[50]. - The company aims to commercialize its products globally, with MRX-4 and Contizole expected to address multi-drug resistant infections[96]. - The company is advancing its clinical pipeline, including the global Phase III clinical trial for MRX-4, which began in 2022 for treating diabetic foot infections[44]. Financial Management and Governance - The company plans to not distribute cash dividends, issue new shares, or convert capital reserves into share capital for the 2022 fiscal year[7]. - The company has received a standard unqualified audit report from PwC Zhong Tian[6]. - The company is committed to maintaining transparency and regular communication with investors through various media channels[20]. - The company has established a governance structure compliant with relevant laws and regulations, including a board of directors and various committees[171]. - The company held a total of 15 board meetings during the reporting period, addressing various financial reports and proposals[195]. - The company has established several specialized committees, including the audit committee, nomination committee, compensation and assessment committee, and strategic committee[199]. Risks and Challenges - The company emphasizes the long R&D cycle and high capital investment required for drug development, which impacts its ability to generate profits in the near term[5]. - The company has highlighted various risk factors in its operations, particularly related to ongoing losses and the potential impact on shareholder returns[5]. - The company faces risks related to its reliance on a single product for revenue generation, as only Kangti Zuoan tablets are currently commercialized[108]. - The company is currently dependent on Zhejiang Huahai for production, posing a risk of supply shortages if production requirements are not met[109]. Industry Context - The global issue of antibiotic resistance poses a significant public health threat, with the company focusing on developing new antibiotics to address this challenge[54]. - The WHO has identified 12 multidrug-resistant bacteria as priority pathogens for new antibiotic development, highlighting the urgent need for effective treatments[57]. - The compound annual growth rate for the proportion of oxazolidinone antibiotics in China from 2017 to 2022 was 23.4%[62]. - The market for antibacterial drugs targeting multi-drug resistant Gram-negative bacteria in China grew from 36.7 million treatment days in 2017 to 59.8 million treatment days in 2022, with a compound annual growth rate (CAGR) of 10.3%[69]. Future Outlook - The company aims to improve its financial performance by optimizing its operational efficiency and product offerings[16]. - The company plans to accelerate the clinical trial process for in-development products and enhance commercialization efforts for already launched products[167]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 191.58 million earmarked for potential mergers and acquisitions[179]. - The company is committed to sustainability initiatives, with a target of reducing carbon emissions by 20% over the next five years[179].

Financial Performance - The company's operating revenue for Q3 2022 was ¥14,473,608.59, representing a year-over-year increase of 163.64%[2] - The net profit attributable to shareholders was -¥66,026,734.90, with no applicable year-over-year comparison due to the negative result[2] - The company experienced a year-to-date net profit attributable to shareholders of -¥173,774,505.72, with no applicable year-over-year comparison due to the negative result[2] - The net loss for the first three quarters of 2022 was ¥173,774,505.72, compared to a net loss of ¥125,500,042.16 in the same period of 2021, representing an increase in losses of approximately 38.5%[18] - The company reported a basic and diluted earnings per share of -¥0.31 for the first three quarters of 2022, compared to -¥0.24 in the same period of 2021[19] Research and Development - Research and development (R&D) expenses totaled ¥49,392,997.52, an increase of 67.75% compared to the same period last year[3] - The ratio of R&D expenses to operating revenue was 341.26%, indicating a decrease of 195.08 percentage points year-over-year[3] - Research and development expenses amounted to ¥114,940,211.45, up from ¥86,620,479.71 in the same period last year, indicating a year-over-year increase of about 32.6%[17] - The company is focusing on expanding its market presence and enhancing its product offerings through increased R&D investment[7] - The company plans to continue focusing on R&D and market expansion strategies to improve future performance and mitigate losses[21] Assets and Liabilities - Total assets reached ¥1,468,974,576.51, reflecting a growth of 126.51% compared to the end of the previous year[3] - Total current assets as of September 30, 2022, amounted to RMB 1,340,580,334.75, an increase from RMB 509,587,048.89 in 2021[11] - Total assets reached RMB 1,468,974,576.51, compared to RMB 648,539,320.38 in the previous year[13] - The total liabilities as of the end of the reporting period were ¥213,414,694.15, slightly up from ¥210,166,885.46 at the end of the previous year[18] - The total equity attributable to shareholders increased to ¥1,255,559,882.36 from ¥438,372,434.92, showing a substantial growth in shareholder equity[18] Cash Flow - The company reported a net cash flow from operating activities of -¥178,919,707.70 for the year-to-date period[2] - The total cash flow from operating activities for the first three quarters of 2022 was not detailed in the provided content, indicating a need for further analysis[21] - In the first three quarters of 2022, the cash inflow from operating activities was CNY 47,059,687.72, compared to CNY 36,924,897.56 in the same period of 2021, representing an increase of approximately 27.6%[22] - The net cash flow from operating activities for the first three quarters of 2022 was -CNY 178,919,707.70, worsening from -CNY 126,592,211.55 in the first three quarters of 2021[22] - The cash inflow from investment activities in the first three quarters of 2022 was CNY 842,619,850.23, a decrease of 47.2% from CNY 1,591,970,777.97 in the same period of 2021[22] Shareholder Information - Total number of common shareholders at the end of the reporting period was 26,442[9] - Genie Pharma held 71,572,817 shares, representing 10.92% of total shares[9] - The company had a total of 128,523,904 restricted shares, accounting for 19.62% of the total share capital[10] Inventory and Costs - The company reported a significant increase in inventory, which rose to RMB 17,924,385.01 from RMB 11,008,530.01[11] - Total operating costs for the first three quarters of 2022 were ¥224,307,692.69, compared to ¥168,395,558.64 in the previous year, reflecting a year-over-year increase of approximately 33.2%[17]